Table 3 Association between circZFR and other clinicopathologic parameters
From: Prognostic and clinicopathologic significance of circZFR in multiple human cancers
Outcome or subgroup | Studies | Participants | Odds ratio (95% CI) | P value | Model | Heterogeneity | |
|---|---|---|---|---|---|---|---|
P value | I2 | ||||||
Age | 11 | 778 | 1.16 (0.86, 1.57) | 0.33 | Fixed | 0.20 | 25% |
Gender | 10 | 683 | 1.02 (0.73, 1.43) | 0.89 | Fixed | 0.60 | 0% |
Tumor size | 10 | 586 | 2.79 (1.52, 5.12) | 0.001 | Random | 0.002 | 66% |
Clinical stage | 9 | 587 | 3.38 (1.49, 7.65) | 0.004 | Random | < 0.0001 | 76% |
DM | 4 | 367 | 1.39 (0.49, 3.94) | 0.53 | Random | 0.007 | 75% |
LNM | 5 | 454 | 3.08 (2.01, 4.71) | < 0.00001 | Fixed | 0.82 | 0% |
Histology grade | 5 | 422 | 3.18 (1.09, 9.30) | 0.03 | Random | 0.0005 | 80% |